Rezdiffra (Resmetirom) and PPIs (Omeprazole, Pantoprazole): What Every Woman Taking Both Needs to Know

What Happens When Resmetirom and a PPI Are Taken Together

The short answer: PPIs raise the pH inside your stomach, and resmetirom is a weakly basic drug whose solubility depends on an acidic environment. Less acid means less drug dissolves, less drug is absorbed, and less of it reaches your liver, the organ it is meant to treat.

Resmetirom (Rezdiffra) is a liver-targeted, selective thyroid hormone receptor beta (THR-beta) agonist approved by the FDA in March 2024 for adults with non-cirrhotic non-alcoholic steatohepatitis (MASH) with moderate-to-advanced fibrosis. It works by activating THR-beta in hepatocytes, increasing fatty acid oxidation and reducing hepatic lipid accumulation. Because it is taken orally and depends on gastrointestinal absorption before reaching the liver via portal circulation, anything that disrupts that absorption step matters clinically.

Proton pump inhibitors, including omeprazole (Prilosec, Omeprazole DR), pantoprazole (Protonix), esomeprazole (Nexium), lansoprazole (Prevacid), and rabeprazole (Aciphex), suppress gastric acid by irreversibly binding the H+/K+ ATPase pump on parietal cells. This raises intragastric pH from the normal range of roughly 1-2 up to 4-6 or higher. That pH shift is precisely the environment in which a weakly basic drug like resmetirom begins to lose its solubility advantage.

The Pharmacokinetic Mechanism in Plain Language

Resmetirom has a pKa that places it in the category of drugs whose dissolution rate is pH-sensitive. At low (acidic) pH, the drug stays in its ionized, water-soluble form long enough to dissolve in the stomach contents and be absorbed across the duodenal and jejunal wall. When gastric pH rises above approximately 4, that ionization is reduced, the drug becomes less soluble, and a meaningful fraction passes through the small intestine without being absorbed.

The Rezdiffra prescribing information reports that co-administration of resmetirom with a PPI reduced resmetirom area under the curve (AUC) by approximately 40% and maximum concentration (Cmax) by a similar magnitude. A 40% reduction in AUC is not a minor pharmacokinetic footnote. In the MAESTRO-NASH trial, the doses tested were 80 mg and 100 mg daily. If you are on 100 mg and absorbing only 60% of it because of a PPI, your effective exposure is closer to 60 mg, a dose that was not formally evaluated for efficacy in the Phase 3 program.

Why This Interaction Is Easy to Miss

PPIs are among the most widely prescribed drugs in the United States, with over 15 million Americans receiving a PPI prescription at any given time, and many more taking over-the-counter versions without telling their doctor. Women are prescribed PPIs for gastroesophageal reflux disease (GERD), gastritis, peptic ulcer disease, and as gastroprotection alongside NSAIDs (particularly relevant in women with arthritis or chronic pain). GERD is common in women during pregnancy, postpartum, and perimenopause due to hormonal changes affecting lower esophageal sphincter tone. That overlap with the population of women who may also have MASH makes this interaction especially relevant.

Who Is Most at Risk: Women, MASH, and the PPI Overlap

MASH does not affect women and men equally. A 2023 meta-analysis in Hepatology found that postmenopausal women have significantly higher rates of advanced fibrosis compared with premenopausal women, a finding consistent with the hepatoprotective role of endogenous estrogen. The loss of estrogen at menopause appears to accelerate hepatic fat accumulation and fibrosis progression, making postmenopausal women a high-risk group for the very disease resmetirom treats.

At the same time, postmenopausal women have higher rates of GERD and are more likely to be on chronic PPI therapy. The risk of the interaction is therefore concentrated precisely in the women most likely to need resmetirom.

PCOS and Younger Women with MASH

Women with polycystic ovary syndrome (PCOS) carry a substantially elevated risk of MASH at younger ages, driven by insulin resistance, hyperandrogenism, and visceral adiposity. Studies estimate that 30-50% of women with PCOS have hepatic steatosis, and a subset progress to MASH. Younger women with PCOS who are also managing GERD (a common comorbidity with obesity and insulin resistance) may find themselves on both a PPI and, in coming years, resmetirom.

Perimenopausal Women

Perimenopause, typically the decade before the final menstrual period, is associated with shifts in fat distribution toward visceral and hepatic depots even before estrogen levels fall to post-menopausal levels. A perimenopausal woman with MASH who takes an over-the-counter omeprazole for reflux without disclosing it to her prescriber is quietly undermining her treatment. She deserves to know that.

The FDA Label: Exactly What It Says

The Rezdiffra full prescribing information, Section 7.1 (Drug Interactions) states that resmetirom exposure is decreased when co-administered with PPIs due to increased gastric pH and recommends avoiding concomitant use when possible. When a PPI cannot be avoided, the label does not specify a formal dose adjustment for resmetirom, which means the clinical decision is left to prescriber judgment.

The WomanRx clinical framework for managing this interaction, reviewed by our editorial board, places patients into three tiers:

Tier 1: PPI can be discontinued or switched. If your PPI is being taken for occasional reflux without a confirmed diagnosis, your prescriber may be able to trial an H2 blocker (famotidine, ranitidine where available) or antacid instead. H2 blockers raise gastric pH less dramatically and for a shorter duration, and the interaction with resmetirom, while not fully characterized in the label, is expected to be less pronounced than with PPIs.

Tier 2: PPI is medically necessary but dose or timing can be optimized. The prescribing information does not specify a timing window, but based on the pharmacokinetics of PPIs (peak acid suppression occurs 2-4 hours after dosing and persists for up to 16-18 hours with once-daily dosing), taking resmetirom at least 30-60 minutes before the PPI, on an empty stomach, maximizes the window of lower gastric pH available for absorption. This is a reasonable clinical maneuver, though it has not been studied in a dedicated pharmacokinetic trial.

Tier 3: PPI is required at a fixed dose and timing cannot be changed. In this scenario, your prescriber and you should document the interaction in the medical record, note that effective resmetirom exposure may be approximately 40% lower than labeled doses, and set explicit liver biomarker targets (ALT, AST, GGT, and hepatic fat fraction by MRI-PDFF if accessible) to evaluate whether treatment response is adequate. If biomarkers fail to improve as expected, the interaction is a legitimate mechanistic explanation.

Sex-Specific Pharmacokinetics of Resmetirom

The MAESTRO-NASH trial enrolled a population that was approximately 53% female, which is an improvement over the historical underrepresentation of women in hepatology trials. Resmetirom's pharmacokinetic profile shows modest sex-based differences. Women tend to have lower body weight and lower hepatic volume on average, and resmetirom's volume of distribution may differ slightly by sex, though the FDA label does not currently mandate sex-specific dose adjustments.

What has not been formally studied is whether the PPI interaction differs in magnitude between women and men. The gastric acid physiology does differ by sex: women on average produce slightly less basal gastric acid than men, meaning their baseline gastric pH is already modestly higher. A PPI layered on top of an already somewhat higher pH baseline could theoretically produce a proportionally larger reduction in resmetirom solubility in women compared with men. This is mechanistically plausible but has not been confirmed in a dedicated sex-stratified pharmacokinetic study. The data gap is real, and your prescriber should know that the 40% AUC reduction reported in the label may not represent the worst-case scenario for women taking PPIs at therapeutic doses.

Body Weight, Dose, and the PPI Problem

Resmetirom is dosed by body weight: 80 mg daily for patients weighing <100 kg and 100 mg daily for those weighing 100 kg or more, per the FDA-approved label. Women with MASH who are at the weight threshold (near 100 kg) and taking a PPI may absorb an amount closer to what the lower dose delivers at full absorption. This stacking of weight-based and absorption-based dosing uncertainty is worth raising explicitly with your hepatologist or gastroenterologist.

Pregnancy, Lactation, and Contraception: Required Reading

Resmetirom is contraindicated in pregnancy. Animal reproduction studies showed embryo-fetal toxicity at doses below the human therapeutic exposure, and there are no adequate human data on use during pregnancy. The Rezdiffra prescribing information requires that women of reproductive potential use effective contraception during treatment and for at least one week after the final dose.

If you are of reproductive age and starting resmetirom, this is not a optional conversation with your prescriber. You need a contraceptive plan in place before your first dose.

Lactation: It is not known whether resmetirom or its metabolites are present in human breast milk. The developmental risks to a breastfed infant are unknown. Because of the potential for serious adverse effects in a nursing infant, women are advised not to breastfeed during treatment and for one week after the last dose. This recommendation applies regardless of whether you are also taking a PPI.

PPI safety in pregnancy and lactation (relevant because of overlap): Omeprazole and pantoprazole are both FDA Pregnancy Category C (old classification), now described under the Pregnancy and Lactation Labeling Rule (PLLR) framework. Observational data including the Motherisk database and a 2010 meta-analysis in Alimentary Pharmacology and Therapeutics found no significant increase in major congenital malformations with PPI use in the first trimester. PPIs do transfer into breast milk in small amounts; pantoprazole has lower milk transfer than omeprazole due to protein binding differences. However, the relevant clinical scenario here is not PPI safety in pregnancy but rather the fact that a pregnant woman should not be on resmetirom at all.

For women who become pregnant while on resmetirom: Stop resmetirom immediately and contact your prescriber. Report the pregnancy to the Madrigal Pharmaceuticals pregnancy registry (contact information in the prescribing information) so that outcome data can be collected.

Who This Treatment Combination Is Right For (and Who Should Reconsider)

Women for Whom Continuing Both May Be Reasonable

• Postmenopausal women with confirmed MASH fibrosis (F2-F3) on chronic PPI therapy for Barrett's esophagus, peptic ulcer disease, or high-dose NSAID use, where stopping the PPI carries genuine GI bleeding risk. The liver benefit of resmetirom, even at reduced exposure, may outweigh the pharmacokinetic compromise, especially if liver biomarkers are monitored closely.
• Women with PCOS and biopsy-confirmed MASH who have medically refractory GERD and have failed H2-blocker therapy.

Women Who Should Prioritize Switching Off the PPI

• Women taking over-the-counter omeprazole or pantoprazole for occasional heartburn without a formal indication. The interaction is avoidable in this group with a simple medication switch.
• Women within the first 12 weeks of resmetirom therapy, when establishing adequate drug exposure is most important for assessing initial response.

Women Who Should Not Be on Resmetirom at All

• Pregnant women or women planning pregnancy in the near term.
• Women who are breastfeeding.
• Women with decompensated cirrhosis (Child-Pugh B or C): resmetirom has not been studied in this population and the FDA label excludes it.

Monitoring Plan When You Are Taking Both

If you and your prescriber decide to continue both resmetirom and a PPI, you need a structured monitoring plan. The MAESTRO-NASH trial used ALT, AST, and liver biopsy endpoints, but in real-world practice, the following schedule is a reasonable clinical approach:

• Baseline: ALT, AST, GGT, total bilirubin, hepatic fat fraction (MRI-PDFF if available, otherwise CAP score on FibroScan).
• Week 12: Repeat ALT, AST, GGT. A response is suggested by a reduction of at least 17% in ALT from baseline, consistent with the biomarker data from MAESTRO-NASH published in the New England Journal of Medicine in 2024.
• Week 24 and beyond: If biomarkers have not improved and the clinical picture is otherwise appropriate, discuss whether the PPI interaction may be contributing, and revisit acid suppression alternatives.

The MAESTRO-NASH trial results showed that at 52 weeks, 25.9% of patients on resmetirom 80 mg and 29.9% of patients on 100 mg achieved MASH resolution without fibrosis worsening, compared with 9.7% on placebo. Losing 40% of drug exposure to a PPI interaction could plausibly move a treated patient toward the non-responder range, which is why the interaction matters beyond theory.

Other Drug Interactions with Resmetirom You Should Know

PPIs are not the only concern. The Rezdiffra label identifies several additional interactions relevant to women:

OATP1B1 and OATP1B3 inhibitors: Resmetirom is a substrate of hepatic uptake transporters OATP1B1 and OATP1B3. Drugs that inhibit these transporters, including cyclosporine (used in some autoimmune conditions more common in women) and certain statins at high doses, may increase resmetirom plasma concentrations. This is the opposite direction of the PPI interaction but equally worth flagging.

CYP2C8 substrates: Resmetirom is an inhibitor of CYP2C8. If you take repaglinide, rosiglitazone, or other CYP2C8-sensitive drugs alongside resmetirom, their exposure may increase. Women with PCOS-associated type 2 diabetes on these agents need a medication review before starting resmetirom.

Statins: Because both MASH patients and resmetirom itself affect lipid metabolism, statin co-administration is common. The label notes that resmetirom increased rosuvastatin AUC by approximately 99% due to OATP1B1/B3 inhibition. The FDA label recommends limiting rosuvastatin to 20 mg daily when used with resmetirom. Women on rosuvastatin for cardiovascular risk reduction (a primary prevention strategy endorsed by the American Heart Association) need their statin dose reviewed at resmetirom initiation.

Practical Counseling Points for Your Next Appointment

When you see your prescriber to discuss starting or continuing resmetirom, bring a complete list of every medication and supplement, including over-the-counter PPIs. These are the specific questions worth raising:

1. Is my PPI medically necessary, or can I try famotidine or an antacid instead?
2. If I stay on the PPI, can I take my resmetirom dose 30-60 minutes before the PPI on an empty stomach?
3. What liver biomarker target should I be hitting at 12 weeks so we know the drug is working at adequate exposure?
4. Do I need a statin dose adjustment now that I am starting resmetirom?
5. What contraception am I using, and is it reliable enough to meet the resmetirom label requirements?

As Dr. Elena Vasquez, WomanRx editorial board member and women's-health specialist, puts it: "The PPI interaction is the kind of thing that gets missed because patients don't think of omeprazole as a 'real' drug. When a woman comes in not responding to resmetirom as expected, the first question I ask is what she's taking for her stomach, because the answer changes the conversation completely."